Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Farmers Insurance
Cipla
Harvard Business School
Teva
Accenture
Chubb
Novartis
Mallinckrodt
Cantor Fitzgerald

Generated: February 25, 2018

DrugPatentWatch Database Preview

Pazopanib hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for pazopanib hydrochloride and what is the scope of pazopanib hydrochloride patent protection?

Pazopanib hydrochloride
is the generic ingredient in one branded drug marketed by Novartis Pharms Corp and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pazopanib hydrochloride has forty patent family members in twenty-five countries.

There are three drug master file entries for pazopanib hydrochloride. One supplier is listed for this compound.
Summary for pazopanib hydrochloride

US Patents and Regulatory Information for pazopanib hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 DISCN No No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Novartis Pharms Corp VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Novartis Pharms Corp VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Novartis Pharms Corp VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 DISCN No No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Novartis Pharms Corp VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 DISCN No No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Novartis Pharms Corp VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for pazopanib hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,858,626 Pyrimidineamines as angiogenesis modulators ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for pazopanib hydrochloride

Supplementary Protection Certificates for pazopanib hydrochloride

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
9 Finland ➤ Sign Up
C/GB10/032 United Kingdom ➤ Sign Up PRODUCT NAME: PAZOPANIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; REGISTERED: UK EU 1/10/628/001 20100614; UK EU 1/10/628/002 20100614; UK EU 1/10/628/003 20100614; UK EU 1/10/628/004 20100614
710 Luxembourg ➤ Sign Up 91710, EXPIRES: 20250614
C025/2010 Ireland ➤ Sign Up SPC025/2010: 20110401, EXPIRES: 20250613
/2010 Austria ➤ Sign Up PRODUCT NAME: PAZOPANIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/10/628/001 - EU/1/10/628/004 20100614
2010 00024 Denmark ➤ Sign Up PRODUCT NAME: PAZOPANIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER HYDROCLORID
1343782/01 Switzerland ➤ Sign Up FORMER OWNER: GLAXOSMITHKLINE LLC, US
C0037 France ➤ Sign Up PRODUCT NAME: PAZOPANIB; REGISTRATION NO/DATE: EU/1/110/628/001 20100614
00456 Netherlands ➤ Sign Up PRODUCT NAME: PAZOPANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT, IN HET BIJZONDER PAZOPANIB HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/10/628/001-004 20100614
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Merck
Deloitte
McKesson
Fish and Richardson
Accenture
Daiichi Sankyo
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot